Preparation of polydopamine-based concave nanoparticles and mild photothermal-anti-inflammatory combination therapy for breast cancer guided by magnetic resonance imaging

Photothermal therapy (PTT) has been widely investigated as a regimen for superficial tumors. However, conventional PTT strategies usually require photothermal temperatures above 50 & DEG;C to achieve significant therapeutic efficacy, which in effect would lead to injury to adjacent normal tissues and meanwhile, the heat generated by the photothermal effect would induce inflammation owing to the damage to cytoplas-mic components. In order to reduce the toxicity of photothermal therapy and increase the efficiency of photothermal tumor destruction, novel strategies are prerequisite for targeted regimen and surveillance of photothermal therapy in real time. In this paper, we reported a concave mesoporous polydopamine-targeting nanotherapeutic agent. We employed B-MPDA as the carrier and encapsulated CQ and ASP to yield B-MPDA/CQ/ASP which was loaded with autophagy inhibitors and anti-inflammatory agents and coated uniformly with MnO2 Nanosheet. With HA functionalizing MnO2 Nanosheet, B-MPDA/CQ/ ASP@MnO2-HA was constituted. The yielded nanoparticles were identified to be advantageous for good biocompatibility, potent targeting and low toxicity. In anti-tumor regimens, the nanoparticles can be applied to hyaluronic acid targeting, mesoporous polydopamine thermotherapy, and autophagy inhibitor sensitization thermotherapy, and simultaneously eliminate the inflammatory effects induced by pho-tothermal therapy. Furthermore, in combination with the anti-inflammatory effect of targeting tumor, this agent can effectively induce apoptosis of cancer cells and significantly improve the efficiency of mild photothermal killing of cancer cells, which provides insight into the development of nanoparticles and application to mild photothermal therapy in the clinical scenario. & COPY; 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Automated summary

Photothermal therapy (PTT) has been widely studied as a treatment for superficial tumors. However, traditional PTT methods often require high temperatures to effectively destroy tumors, resulting in damage to normal tissues and inflammatory responses. To address these issues, a novel concave mesoporous polydopamine-targeting nanotherapeutic agent was developed. This agent demonstrated good biocompatibility, strong targeting abilities, and low toxicity. It could be used for hyaluronic acid targeting, mesoporous polydopamine thermotherapy, autophagy inhibitor sensitization thermotherapy, and elimination of inflammation induced by photothermal therapy, leading to improved efficiency of mild photothermal therapy for cancer treatment.